Back to Screener

Healthcare

Instil Bio, Inc.(TIL)

Live Price

Offline

$7.50

-0.79% today

1Y Change

-74.87%

Window

Jun 23, 2025 โ†’ Jun 18, 2026

Market Cap
$50.00M
Revenue Growth
0.0%
EPS Growth
+6.1%
Dividend Yield
0.0%

Coverage: 249 bars ยท Jun 23, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Instil Bio, Inc. (TIL) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $7.50 and down 74.9% across the available one-year price window (Jun 23, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +6.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +6.1%, free cash flow +44.3% with operating margin 0.0% and ROIC -39.5%. Stock Foundry combines TIL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

TIL

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

TIL Max Drawdown

-79.34%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for TIL and SPY.

Calendar-year return history is still loading or unavailable.

EPS Consensus

-0.27

Range -0.27 โ†’ -0.27

No analyst count

vs prior: +19.7%

Revenue Outlook

$0.0B

Range $0.0B โ†’ $0.0B

No analyst count

Consensus Spread

EPS spread0.0%
Revenue spreadโ€”

Lower spread suggests tighter agreement across covering analysts.

Trend

EPS trend

Consensus average across visible periods

-0.27
Latest visible period
Q3 2025Q4 2026
6 visible pointstrend: +19.7%

Trend

Revenue trend

Average analyst revenue estimate

$0.0B
Latest visible period
Q3 2025Q4 2026
6 visible points

Timeline

Analyst forecast ladder

Sorted by period end date. Includes both cached rows and live fallbacks from FMP.

Q4 2026
Ends Dec 31, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.27
-0.27 to -0.27
No analyst count
EPS: No analyst count
May 2, 07:57 AM UTC
stable/analyst-estimates
Q3 2026
Ends Sep 30, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.33
-0.33 to -0.33
No analyst count
EPS: No analyst count
May 2, 07:57 AM UTC
stable/analyst-estimates
Q2 2026
Ends Jun 30, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.42
-0.42 to -0.42
No analyst count
EPS: No analyst count
May 2, 07:57 AM UTC
stable/analyst-estimates
Q1 2026
Ends Mar 31, 2026
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.59
-0.59 to -0.59
No analyst count
EPS: No analyst count
May 2, 07:57 AM UTC
stable/analyst-estimates
Q4 2025
Ends Dec 31, 2025
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-2.04
-2.04 to -2.04
No analyst count
EPS: No analyst count
May 2, 07:57 AM UTC
stable/analyst-estimates
Q3 2025
Ends Sep 30, 2025
quarter
Revenue
$0.0B
$0.0B to $0.0B
EPS
-2.35
-2.35 to -2.35
No analyst count
EPS: No analyst count
May 2, 07:57 AM UTC
stable/analyst-estimates

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.